Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
Key Highlights
- ➤Relmada (RLMD) will report third-quarter 2026 financial results November 12, 2026.
- ➤Conference call and webcast scheduled for 4:30 PM ET on November 12.
- ➤Lead candidates NDV-01 and sepranolone are advancing through clinical development.
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress.
Conference Call and Webcast Information: * Date: Thursday, November 12, 2026 at 4:30 PM ET * Participant Dial-in (US): 1-800-717-1738 * Participant Dial-in (International): 1-646-307-1865 * Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at https://ir.relmada.com/investors/events/.
Get started
Create a free account to read the full story.